IBRX ImmunityBio, Inc.
Company Updates ·
MiNK reported first quarter 2026 results and said cash and cash equivalents were approximately $9.5 million at March 31, 2026. Preliminary data from the trial are expected in the second half of 2026.
The company amended its sales agreement with Jefferies and filed a new prospectus supplement. It also confirmed a higher authorized share count.
A federal court preliminarily approved the settlement of three shareholder derivative suits naming ImmunityBio's current and former officers and directors. The company agrees to governance reforms and expects its insurer to pay the plaintiffs' attorneys' fees, which their counsel plans to ask the court to set at up to $1,400,000. The final hearing is November 4, 2025.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $113.3 million | $14.7 million |
| Research and development | $190.1 million | |
| Net income (loss) | -$351.4 million | -$413.6 million |
| Cash from operations | -$304.9 million | -$391.2 million |
| Cash and equivalents | $88.3 million | $143.4 million |
| Short-term investments | $154.5 million | $6.4 million |
Our latest story on this, dated Dec 29, 2025: "ImmunityBio adds up to $459,972,480 to its at-the-market stock program". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 8, 2025: "ImmunityBio gets preliminary court approval of shareholder derivative lawsuit settlement". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 8, 2025: "ImmunityBio gets preliminary court approval of shareholder derivative lawsuit settlement". The story links the filing or release it is based on. Read the story.
ImmunityBio, Inc. trades under the ticker IBRX on NASDAQ.
ImmunityBio, Inc. is listed on NASDAQ. Our directory also records these other listings: DUS:26CA; FWB:26CA; GETTEX:26CA; HAM:26CA; HAN:26CA; LS:A2QQ2E; LSX:A2QQ2E; MUN:26CA; SWB:26CA; TRADEGATE:26CA; XETR:26CA.
The SEC Central Index Key (CIK) for ImmunityBio, Inc. is 1326110. Its filings are on SEC EDGAR.
1,059,836,273 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-04.
Our directory records ImmunityBio, Inc. under United States.
Our directory classifies ImmunityBio, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for ImmunityBio, Inc. is US45256X1037.
aibio.space lists ImmunityBio, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
$113.3 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
ImmunityBio, Inc. reported a net loss of $351.4 million for the fiscal year ended Dec 31, 2025, and used $304.9 million of cash in operations, per its annual report to the SEC.
$357.4 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Reported a financing. SEC Form 424B5. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 8-K (Items 8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,2.02,7.01,8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,7.01,9.01). Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Reported a financing. SEC Form 424B5. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio